Journal
NEUROSURGERY CLINICS OF NORTH AMERICA
Volume 23, Issue 4, Pages 653-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nec.2012.06.012
Keywords
Cushing disease; Failed transphenoidal surgery; Recurrent Cushing disease; Somatostatin receptor ligands; Pasireotide; Glucocorticoid receptor antagonist; Mifepristone; Adrenal steroidogenesis inhibitors
Categories
Funding
- Corcept Therapeutics, Inc
- Novartis
Ask authors/readers for more resources
Recent evidence supports the notion that the incidence of Cushing disease is higher than previously thought. Transphenoidal surgery, in the hands of experienced neurosurgeons, is currently considered the first-line treatment of choice. However, an examination of remission and recurrence rates in long-term follow-up studies reveals that potentially up to 40% to 50% of patients could require additional treatment. If left untreated, the resultant morbidity and mortality are high. Successful clinical management of patients with Cushing disease remains a challenge. The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available